Target intelligence / Profile preview

Host–microbiota gut ecosystem

Molecular classification
Other
01

Overview

The host–microbiota gut ecosystem is a complex symbiotic network comprising trillions of microorganisms, including bacteria, fungi, viruses, and archaea, interacting with the human gastrointestinal tract. This ecosystem is fundamental to human physiology, contributing to the fermentation of non-digestible dietary fibers into short-chain fatty acids (SCFAs), the synthesis of vitamins (e.g., B and K), and the development and regulation of the mucosal immune system (NIH, 2023). It acts as a functional organ that maintains intestinal barrier integrity and protects against the colonization of enteric pathogens through competitive exclusion. Disruptions to this delicate balance, known as dysbiosis, are strongly associated with diverse conditions such as inflammatory bowel disease (IBD), obesity, type 2 diabetes, and even neurological disorders via the gut-brain axis (Nature Reviews Microbiology, 2022). Pharmacological and therapeutic strategies targeting this ecosystem include the use of live biotherapeutic products (LBPs), fecal microbiota transplantation (FMT), and precision prebiotics designed to selectively promote beneficial taxa. Unlike traditional single-protein targets, the gut ecosystem requires a systems-biology approach to modulate community-wide metabolic outputs and host-microbe signaling pathways.

Other names
Gut microbiomeGut microbiotaIntestinal floraGastrointestinal ecosystemHuman gut microbiome
02

Mechanism of action

Modulation of microbial community composition, restoration of taxonomic diversity, and alteration of metabolite production (e.g., short-chain fatty acids) to restore host homeostasis (Nature Reviews Gastroenterology & Hepatology, 2023).

03

Biological functions

Nutrient metabolismImmune system modulationPathogen colonization resistanceIntestinal barrier maintenanceVitamin synthesis
04

Disease associations

Inflammatory bowel diseaseClostridioides difficile infectionObesityType 2 diabetesColorectal cancerIrritable bowel syndromeNeuropsychiatric disorders
05

Safety considerations

Risk of systemic infection (bacteremia)Transfer of antimicrobial resistance genesUnpredictable long-term ecological shiftsLack of standardization in live biotherapeutic products
06

Interacting drugs

Rifaximin

7 more in the full profile.

07

Biomarkers

Alpha diversity (Shannon index)Firmicutes/Bacteroidetes ratioFecal butyrate concentrationFecal calprotectinAkkermansia muciniphila abundance

Beyond the preview

Go deeper on Host–microbiota gut ecosystem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Host–microbiota gut ecosystem.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call